Literature DB >> 34871620

Prediction models of treatment response in lupus nephritis.

Isabelle Ayoub1, Bethany J Wolf2, Linyu Geng3, Huijuan Song1, Aastha Khatiwada4, Betty P Tsao3, Jim C Oates5, Brad H Rovin6.   

Abstract

In order to develop prediction models of one-year treatment response in lupus nephritis, an approach using machine learning to combine traditional clinical data and novel urine biomarkers was undertaken. Contemporary lupus nephritis biomarkers were identified through an unbiased PubMed search. Thirteen novel urine proteins contributed to the top 50% of ranked biomarkers and were selected for measurement at the time of lupus nephritis flare. These novel markers along with traditional clinical data were incorporated into a variety of machine learning algorithms to develop prediction models of one-year proteinuria and estimated glomerular filtration rate (eGFR). Models were trained on 246 individuals from four different sub-cohorts and validated on an independent cohort of 30 patients with lupus nephritis. Seven models were considered for each outcome. Three-quarters of these models demonstrated good predictive value with areas under the receiver operating characteristic curve over 0.7. Overall, prediction performance was the best for models of eGFR response to treatment. Furthermore, the best performing models contained both traditional clinical data and novel urine biomarkers, including cytokines, chemokines, and markers of kidney damage. Thus, our study provides further evidence that a machine learning approach can predict lupus nephritis outcomes at one year using a set of traditional and novel biomarkers. However, further validation of the utility of machine learning as a clinical decision aid to improve outcomes will be necessary before it can be routinely used in clinical practice to guide therapy.
Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lupus nephritis; outcomes in lupus nephritis; prediction models in lupus nephritis; urine biomarkers

Mesh:

Substances:

Year:  2021        PMID: 34871620      PMCID: PMC8792241          DOI: 10.1016/j.kint.2021.11.014

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   18.998


  18 in total

1.  Neutrophil exocytosis induces podocyte cytoskeletal reorganization and proteinuria in experimental glomerulonephritis.

Authors:  Dawn J Caster; Erik A Korte; Min Tan; Michelle T Barati; Shweta Tandon; T Michael Creed; David J Salant; Jessica L Hata; Paul N Epstein; Hui Huang; David W Powell; Kenneth R McLeish
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-23

2.  Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.

Authors:  Richard Furie; Kathy Nicholls; Tien-Tsai Cheng; Frederic Houssiau; Ruben Burgos-Vargas; Shun-Le Chen; Jan L Hillson; Stephanie Meadows-Shropshire; Michael Kinaszczuk; Joan T Merrill
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

Review 3.  The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future.

Authors:  Isabelle Ayoub; Clarissa Cassol; Salem Almaani; Brad Rovin; Samir V Parikh
Journal:  Adv Chronic Kidney Dis       Date:  2019-09       Impact factor: 3.620

4.  Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus.

Authors:  Heather N Reich; Dafna D Gladman; Murray B Urowitz; Joanne M Bargman; Michelle A Hladunewich; Wendy Lou; Steve C P Fan; Jiandong Su; Andrew M Herzenberg; Daniel C Cattran; Joan Wither; Carol Landolt-Marticorena; James W Scholey; Paul R Fortin
Journal:  Kidney Int       Date:  2011-01-19       Impact factor: 10.612

5.  Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus.

Authors:  C C Mok; Raymond C L Kwok; Paul S F Yip
Journal:  Arthritis Rheum       Date:  2013-08

6.  Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis.

Authors:  Juan M Mejia-Vilet; John P Shapiro; Xiaolan L Zhang; Cristino Cruz; Grant Zimmerman; R Angélica Méndez-Pérez; Mayra L Cano-Verduzco; Samir V Parikh; Haikady N Nagaraja; Luis E Morales-Buenrostro; Brad H Rovin
Journal:  Arthritis Rheumatol       Date:  2021-01-12       Impact factor: 10.995

Review 7.  Induction Therapy for Lupus Nephritis: the Highlights.

Authors:  Isabelle Ayoub; Jessica Nelson; Brad H Rovin
Journal:  Curr Rheumatol Rep       Date:  2018-08-14       Impact factor: 4.592

8.  Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders.

Authors:  Samir V Parikh; Ana Malvar; Huijuan Song; Valeria Alberton; Bruno Lococo; Jay Vance; Jianying Zhang; Lianbo Yu; Brad H Rovin
Journal:  Lupus Sci Med       Date:  2015-11-18

9.  Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis.

Authors:  Rachael D Wright; Michael W Beresford
Journal:  Am J Physiol Renal Physiol       Date:  2018-09-12

10.  Variable selection and validation in multivariate modelling.

Authors:  Lin Shi; Johan A Westerhuis; Johan Rosén; Rikard Landberg; Carl Brunius
Journal:  Bioinformatics       Date:  2019-03-15       Impact factor: 6.937

View more
  3 in total

Review 1.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

2.  The first-year course of urine MCP-1 and its association with response to treatment and long-term kidney prognosis in lupus nephritis.

Authors:  Abril A Pérez-Arias; R Angélica Méndez-Pérez; Cristino Cruz; María Fernanda Zavala-Miranda; Juanita Romero-Diaz; Sofía E Márquez-Macedo; Roque A Comunidad-Bonilla; C Carolina García-Rueda; Juan M Mejía-Vilet
Journal:  Clin Rheumatol       Date:  2022-09-15       Impact factor: 3.650

Review 3.  Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs).

Authors:  Diederik De Cock; Elena Myasoedova; Daniel Aletaha; Paul Studenic
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-06-30       Impact factor: 3.625

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.